[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.209.104.7. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,154
Citations 0
Biotech Innovations
February 13, 2018

Hemophilia Gene Therapies Show Promise

JAMA. 2018;319(6):539. doi:10.1001/jama.2018.0524

Early results from trials of investigational hemophilia A and B gene therapies were recently published in the New England Journal of Medicine. Both ongoing trials demonstrated substantial and sustained increases in endogenous clotting factor activity and reductions in bleeding and exogenous factor use. Hemophilia A and B are caused by genetic mutations that result in blood clotting factor VIII and IX deficiency, respectively. Hemophilia A is 6 times more common than hemophilia B.

×